Although research investigating that T2DM may alter brain inflammation in AD is limited, there is a great possibility that T2DM could accentuate microglial activation, neuroinflammation, and vascular inflammatory/oxidative injury in AD brains through mechanisms mediated by RAGE and other pattern-recognition receptors, and the cascade of cytokine and chemokines. The gene discussed is AGER; the disease is Alzheimer disease.